Roche heirs bid goodbye to ‘unsustainable’ philanthropy
The heirs of Switzerland’s pharmaceutical company Roche are ending an era as philanthropic donors for major nature conservation projects, the NZZ am Sonntag reported.
This content was published on
2 minutes
Русский
ru
Концерн Roche прощается с «нерентабельной» филантропией
Their Mava Foundation, established 25 years ago, will shut down next year. “The traditional form of philanthropy has failed,” Roche Vice Chairman Andre Hoffmann told the German-language weekly in an interview published on Sunday.
Transferring money because you have a guilty conscience doesn’t do any good, the 63-year-old foundation president and economist explained.
“You may feel good about it yourself, but it doesn’t solve the problems,” he said. “Projects that exist only as long as we pay and stop when we withdraw are misguided.”
At last count, the Mava Foundation was involved in 180 projects with 120 partners. Many managed to continue and survive on their own, according to Hoffmann, spokesman for the Roche shareholder pool.
The foundation’s closure has been in the works for years.
Founded in 1994
The foundation, based in the town of Gland, canton Vaud, had been established in 1994. Launched by Hoffmann’s father, Luc, its original aim was to protect unique landscapes such as the Camargue.
Hoffmann told the newspaper he and his children would continue to support projects provided that they are based on a business model that ensured survival.
“The success of a project should not depend on the donor,” he stressed.
Hoffmann, who is involved in more than a dozen charitable activities, also called for greater accountability from companies when consumption of their products causes harm.
Food manufacturers, for example, should have to answer for health damage caused by excessive sugar content in their products, he said.
Greenwashing
He also criticised the way many companies still develop products without paying attention to their ecological footprint. It is only later that something is donated.
These companies, he argues, are guilty of greenwashing. “It’s not how you spend the money that matters, it’s how you do it,” he said.
Hoffmann believes the financial industry has the highest potential to make an impact because “it determines where the capital of pension funds and other investors goes”.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Eight Swiss in Bloomberg billionaire ‘rich list’
This content was published on
In the latest version of the Bloomberg Billionaires Index, eight Swiss or Swiss-resident names figure among the 500 richest people in the world.
Swiss pharma industry fights lower drug prices in the US
This content was published on
A proposed US law aims to lower prescription drug prices. But Big Pharma is pulling out all the stops to lobby against it.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.